43 related articles for article (PubMed ID: 19616266)
1. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population.
Fukami A; Adachi H; Yamagishi S; Matsui T; Ueda S; Nakamura K; Enomoto M; Otsuka M; Kumagae S; Nanjo Y; Kumagai E; Esaki E; Murayama K; Hirai Y; Imaizumi T
Metabolism; 2009 Dec; 58(12):1688-93. PubMed ID: 19616266
[TBL] [Abstract][Full Text] [Related]
2. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study.
Rodríguez de Fonseca F; Medina-Paz F; Sapozhnikov M; Hurtado-Guerrero I; Rubio L; Martín-de-Las-Heras S; Requena-Ocaña N; Flores-López M; Fernández-Arjona MDM; Rivera P; Serrano A; Serrano P; C Zapico S; Suárez J
Toxics; 2024 Feb; 12(3):. PubMed ID: 38535924
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA as a Biomarker for Acute Central Serous Chorioretinopathy: A Case-Control Study.
Hashida N; Asao K; Hara C; Quantock AJ; Saita R; Kurakami H; Maruyama K; Nishida K
Front Med (Lausanne); 2022; 9():938600. PubMed ID: 35801206
[TBL] [Abstract][Full Text] [Related]
4. DNA-Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice.
Koga Y; Sotokawauchi A; Higashimoto Y; Nishino Y; Hashizume N; Kakuma T; Akiba J; Tanaka Y; Matsui T; Yagi M; Yamagishi SI
Oxid Med Cell Longev; 2021; 2021():9932311. PubMed ID: 34413930
[TBL] [Abstract][Full Text] [Related]
5. Increased Serum Concentrations of High Mobility Group Box 1 (HMGB1) Protein in Children with Autism Spectrum Disorder.
Makris G; Chouliaras G; Apostolakou F; Papageorgiou C; Chrousos GP; Papassotiriou I; Pervanidou P
Children (Basel); 2021 Jun; 8(6):. PubMed ID: 34198762
[TBL] [Abstract][Full Text] [Related]
6. Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.
Garrido MM; Ribeiro RM; Krüger K; Pinheiro LC; Guimarães JT; Holdenrieder S
In Vivo; 2021; 35(4):2207-2212. PubMed ID: 34182498
[TBL] [Abstract][Full Text] [Related]
7. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.
Land WG
Mol Diagn Ther; 2020 Jun; 24(3):251-262. PubMed ID: 32248387
[TBL] [Abstract][Full Text] [Related]
8. High-mobility group box 1 at the time of parturition in women with gestational diabetes mellitus.
Hill AV; Menon R; Perez-Patron M; Carrillo G; Xu X; Taylor BD
Am J Reprod Immunol; 2019 Nov; 82(5):e13175. PubMed ID: 31353785
[TBL] [Abstract][Full Text] [Related]
9. Post-translational modifications of high mobility group box 1 and cancer.
Richard SA; Jiang Y; Xiang LH; Zhou S; Wang J; Su Z; Xu H
Am J Transl Res; 2017; 9(12):5181-5196. PubMed ID: 29312476
[TBL] [Abstract][Full Text] [Related]
10. Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and the activity of semicarbazide-sensitive amine oxidase.
Koborová I; Gurecká R; Csongová M; Volkovová K; Szökő É; Tábi T; Šebeková K
Croat Med J; 2017 Apr; 58(2):106-116. PubMed ID: 28409494
[TBL] [Abstract][Full Text] [Related]
11. Role of Redox Status in Development of Glioblastoma.
Salazar-Ramiro A; Ramírez-Ortega D; Pérez de la Cruz V; Hérnandez-Pedro NY; González-Esquivel DF; Sotelo J; Pineda B
Front Immunol; 2016; 7():156. PubMed ID: 27199982
[TBL] [Abstract][Full Text] [Related]
12. Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.
Pilzweger C; Holdenrieder S
Diagnostics (Basel); 2015 Jun; 5(2):219-53. PubMed ID: 26854151
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.
Lazo M; Halushka MK; Shen L; Maruthur N; Rebholz CM; Rawlings AM; Hoogeveen RC; Brinkley TE; Ballantyne CM; Astor BC; Selvin E
Am Heart J; 2015 Nov; 170(5):961-7. PubMed ID: 26542505
[TBL] [Abstract][Full Text] [Related]
14. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.
de Souza AW; van der Geest KS; Brouwer E; Pinheiro FA; Oliveira AC; Sato EI; Andrade LE; Bijl M; Westra J; Kallenberg CG
Arthritis Res Ther; 2015 Jun; 17(1):158. PubMed ID: 26062541
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells.
Zhang J; Liu C; Hou R
Chin J Cancer Res; 2014 Dec; 26(6):658-68. PubMed ID: 25561763
[TBL] [Abstract][Full Text] [Related]
16. HMGB1 in health and disease.
Kang R; Chen R; Zhang Q; Hou W; Wu S; Cao L; Huang J; Yu Y; Fan XG; Yan Z; Sun X; Wang H; Wang Q; Tsung A; Billiar TR; Zeh HJ; Lotze MT; Tang D
Mol Aspects Med; 2014 Dec; 40():1-116. PubMed ID: 25010388
[TBL] [Abstract][Full Text] [Related]
17. Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study.
Momma H; Niu K; Kobayashi Y; Huang C; Chujo M; Otomo A; Tadaura H; Miyata T; Nagatomi R
Diabetol Metab Syndr; 2014 Mar; 6(1):33. PubMed ID: 24602408
[TBL] [Abstract][Full Text] [Related]
18. Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.
Yamagishi S
Diabetes; 2013 Oct; 62(10):e26. PubMed ID: 24065804
[No Abstract] [Full Text] [Related]
19. High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients.
Zhu N; Yuan W; Zhou Y; Liu J; Bao J; Hao J; Miao W
J Artif Organs; 2011 Jun; 14(2):125-32. PubMed ID: 21442152
[TBL] [Abstract][Full Text] [Related]
20. High mobility group protein B1 (HMGB1) in Asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls.
Hou C; Zhao H; Liu L; Li W; Zhou X; Lv Y; Shen X; Liang Z; Cai S; Zou F
Mol Med; 2011; 17(7-8):807-15. PubMed ID: 21380479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
